Funding transnational collaborative research through joint transnational calls is one of the major objectives of E-Rare. This is the most important and effective joint activity to enhance the cooperation between European scientists working on rare diseases and thus reducing the fragmentation of research in this field. E-Rare launches calls on a yearly basis. The topic and eligibility criteria are specified every year and therefore may vary from one call to the other.

France
Germany
Israel
Spain
ALS-degeneration
The molecular basis for neurodegeneration and muscle atrophy in ALS

Project Coordinator

Department of Physiology and Pharmacology University of Tel Aviv
Tel Aviv
Israel

Partners

Alberto Redondo 12th University Hospital Madrid Madrid, Spain
Edgar Gomes Group Myologie University Paris VI Paris Paris, France
Filippo Del Bene Unité de Génétique et Biologie du Développement, U934/UMR3215 Istitute Curie Paris Paris, France
Marcus Krüger Biomolecular Mass Spectrometry Max Planck Institute for Heart and Lung Research Bad Nauheim Bad Nauheim, Germany
Roded Sharan School of Computer Science Tel Aviv University Tel Aviv Tel Aviv, Israel

The basic mechanism of neurodegeneration taking place in Amyotrophic Lateral Sclerosis (ALS) is not yet understood, reflecting an unmet and urgent medical need. For some reason that we do not understand one of the early signs seen in ALS, is a disruption of the neuromuscular junction (NMJ) - the place where the motor neurons meets the muscle. This disruption can possibly cause the nerve cells failing and the muscle atrophy, which occurs in the disease. The goal of this research is to elucidate key molecular mechanisms in ALS etiology by 1) specifically study how the motor protein dynein maintain the NMJ stable and keeps the neurons healthy. 2) Using large-scale screening methods we will look for novel factors from the neuron immediate environment that are required for maintaining vigorous nerve and muscle cells. Successful completion of this plan will open new avenues for future drug development and delivery strategies.

 

E-Rare 2012 - Created by Toussaint Biger